Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH): AST2303 tablets receive approval for drug clinical trials.

23/09/2024

Ails (688578.SH) announced recently that the company has received the approval and issuance of the "Drug Clinical ..." by the National Medical Products Administration.

Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH) announced that the company recently received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration, approving the clinical trial of AST2303 tablets in adult patients with advanced non-small cell lung cancer carrying the EGFR C797S mutation. The announcement states that AST2303 tablets (ABK3376 tablets) are a highly selective and brain-permeable new generation EGFR oral small molecule inhibitor that can effectively inhibit the EGFRC797S mutation.

New stock news: Guangdong CHJ Industry (002345.SZ) submitted to the Hong Kong Stock Exchange that by 2024, it will be ranked first among fashion jewelry companies in mainland China.

September comparison of the five-dimensional industry by EB Securities: Expected market style mainly tends towards growth and balance.

CMSC: In the second quarter, which specific sectors in the A-share market saw improvements in supply and demand? Which sectors saw an increase in intrinsic value return on investment?

New stock news: Guangdong CHJ Industry (002345.SZ) submitted to the Hong Kong Stock Exchange that by 2024, it will be ranked first among fashion jewelry companies in mainland China.

September comparison of the five-dimensional industry by EB Securities: Expected market style mainly tends towards growth and balance.

CMSC: In the second quarter, which specific sectors in the A-share market saw improvements in supply and demand? Which sectors saw an increase in intrinsic value return on investment?